Inovio Pharmaceuticals Inc(INO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.18 | Insider Own | 0.38% | Shs Outstand | 103.4M | Perf Week | -8% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | 44.1% | Insider Trans | - | Shs Float | 103.0M | Perf Month | -36.74% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.2 | Inst Own | 38.98% | Short Float | 20.68% | Perf Quarter | 14% |
| Income | -0.07B | P/S | - | EPS this Y | 57.83% | Inst Trans | 1.64% | Short Ratio | 4.71 | Perf Half Y | -31.09% |
| Sales | 0.00B | P/B | 14.54 | EPS next 5Y | 61.91% | ROA | -114.64% | Short Interest | 21.30M | Perf YTD | -55.64% |
| Book/sh | 0.05 | P/C | 2.18 | EPS past 3/5Y | 49.51% 32.44% | ROE | -409.87% | 52W High | -71.63% ($2.72) | Perf Year | -68.24% |
| Cash/sh | 0.35 | P/FCF | - | Sales past 3/5Y | -81.47% -61.18% | ROIC | -711.67% | 52W Low | 37.04% ($0.56) | Perf 3Y | -82.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 54.89% | Gross Margin | - | Volatility(W/M) | 20.88% 12.75% | Perf 5Y | -99.1% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | -99% |
| Dividend Ex-Date | - | Quick Ratio | 1 | EPS Q/Q | 87.83% | Profit Margin | - | RSI (14) | 33.54 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1 | Sales Q/Q | - | SMA20 | -22.65% ($1) | Beta | 1.64 | Target Price | $3.17 |
| Payout | - | Debt/Eq | 1.83 | Earnings | 2026/8/12 | SMA50 | -32.98% ($1.15) | Rel Volume | 2.13 | Prev Close | $0.93 |
| Employees | 112 | LT Debt/Eq | 1.17 | EPS/Sales Surpr. | 67.7% - | SMA200 | -39.15% ($1.27) | Avg Volume(3M) | 4.53M | Price | $0.77 |
| IPO | 1998/12/8 | Option/Short | Yes/Yes | Trades | 9847 | Volume | 9,642,471 | Change | -16.89% |
🧬 Inovio Pharmaceuticals (INO) is a US clinical-stage biotechnology company developing DNA-based medicines. Using its proprietary electroporation delivery device, the company is researching immunotherapy candidates for HPV-related diseases, cancers, and infectious diseases. Commercial product revenue remains limited, and progress in its clinical pipeline is the key driver of the company's valuation.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded more than usual. That is 213% of its average volume.
INO has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +57.8% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.1%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GENZ VanEck Digital Native Economy ETF 16M It ranks #381 of 594 in the industry
Based on market cap of $80M.
RLYB#378 Rallybio Corp $83M PER 3.4 
CRBP#379 Corbus Pharmaceuticals Holdings Inc $82M PER - 
NTRB#380 Nutriband Inc $81M PER - INO#381 Inovio Pharmaceuticals Inc $80M PER - 
OKYO#382 OKYO Pharma Limited $79M PER - 
FAQ
What kind of company is INO?
INO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INO?
The market cap of INO is approximately $80M, ranking 4,609 within its sector.
What is the 52-week high and low for INO?
INO has recorded a 52-week high of $2.72 and a low of $0.56.
